• 1
    Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36: 36571.
  • 2
    Kyndt X, Reumaux D, Bridoux F, Tribout B, Bataille P, Hachulla E, et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999; 106: 52733.
  • 3
    Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43: 202533.
  • 4
    Girard T, Mahr A, Noel LH, Cordier JF, Lesavre P, Andre MH, et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001; 40: 14751.
  • 5
    Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St Clair EW, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147: 6119.
  • 6
    Kalsch AI, Csernok E, Munch D, Birck R, Yard BA, Gross W, et al. Use of highly sensitive C-reactive protein for followup of Wegener's granulomatosis. J Rheumatol 2010; 37: 231925.
  • 7
    Hind CR, Winearls CG, Lockwood CM, Rees AJ, Pepys MB. Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration. Clin Nephrol 1984; 21: 3415.
  • 8
    Sproson EL, Jones NS, Al-Deiri M, Lanyon P. Lessons learnt in the management of Wegener's granulomatosis: long-term follow-up of 60 patients. Rhinology 2007; 45: 637.
  • 9
    Li CG, Reynolds I, Ponting JM, Holt PJ, Hillarby MC, Kumar S. Serum levels of vascular endothelial growth factor (VEGF) are markedly elevated in patients with Wegener's granulomatosis. Br J Rheumatol 1998; 37: 13036.
  • 10
    Hergesell O, Andrassy K, Nawroth P. Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost 1996; 75: 8928.
  • 11
    Boehme MW, Schmitt WH, Youinou P, Stremmel WR, Gross WL. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med 1996; 101: 38794.
  • 12
    Iwakawa J, Matsuyama W, Kubota S, Mitsuyama H, Suetsugu T, Watanabe M, et al. Increased serum vascular endothelial growth factor levels in microscopic polyangiitis with pulmonary involvement. Respir Med 2006; 100: 172433.
  • 13
    Bjerkeli V, Halvorsen B, Damas JK, Nordoy I, Yndestad A, Aukrust P, et al. Expression of matrix metalloproteinases in patients with Wegener's granulomatosis. Ann Rheum Dis 2004; 63: 165963.
  • 14
    De Leeuw K, Sanders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005; 64: 7539.
  • 15
    Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al, for the International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001; 44: 91220.
  • 16
    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 22132.
  • 17
    Kokkotou E, Conboy LA, Ziogas DC, Quilty MT, Kelley JM, Davis RB, et al. Serum correlates of the placebo effect in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 285e81.
  • 18
    Grip O, Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One 2009; 4: e5263.
  • 19
    Friese RS, Rao F, Khandrika S, Thomas B, Ziegler MG, Schmid-Schonbein GW, et al. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens 2009; 31: 52133.
  • 20
    Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al, for the Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate [published erratum appears in Ann Intern Med 2008;149:519]. Ann Intern Med 2006; 145: 24754.
  • 21
    Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289300.
  • 22
    Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 325.
  • 23
    Harris EK. Statistical principles underlying analytic goal-setting in clinical chemistry. Am J Clin Pathol 1979; 72: 37482.
  • 24
    R&D Systems web site. URL:
  • 25
    Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells: effects of tumour necrosis factor α, interleukin 1 and phorbol ester. Biochem J 1993; 296: 8039.
  • 26
    Cornelius LA, Nehring LC, Roby JD, Parks WC, Welgus HG. Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol 1995; 105: 1706.
  • 27
    Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006; 69: 63645.
  • 28
    Park JA, Shin KS, Kim YW. Polymorphism of matrix metalloproteinase-3 promoter gene as a risk factor for coronary artery lesions in Kawasaki disease. J Korean Med Sci 2005; 20: 60711.
  • 29
    Ikeda K, Ihara K, Yamaguchi K, Muneuchi J, Ohno T, Mizuno Y, et al. Genetic analysis of MMP gene polymorphisms in patients with Kawasaki disease. Pediatr Res 2008; 63: 1825.
  • 30
    Shimizu C, Matsubara T, Onouchi Y, Jain S, Sun S, Nievergelt CM, et al. Matrix metalloproteinase haplotypes associated with coronary artery aneurysm formation in patients with Kawasaki disease. J Hum Genet 2010; 55: 77984.
  • 31
    Matsuyama A, Sakai N, Ishigami M, Hiraoka H, Kashine S, Hirata A, et al. Matrix metalloproteinases as novel disease markers in Takayasu arteritis. Circulation 2003; 108: 146973.
  • 32
    Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002; 61: 1616.